Id: acc0435
Group: 1sens
Protein: CSE1L
Gene Symbol: CSE1L
Protein Id: P55060
Protein Name: XPO2_HUMAN
PTM: phosphorylation
Site: unclear
Site Sequence:
Disease Category: Cancer
Disease: Colorectal Cancer
Disease Subtype:
Disease Cellline: HT29
Disease Info:
Drug: vemurafenib + sorafenib
Drug Info: "Vemurafenib is a BRAF kinase inhibitor used for the treatment of unresectable or metastatic melanoma with BRAF V600 mutation. Sorafenib is a multi-kinase inhibitor approved for advanced hepatocellular carcinoma, renal cell carcinoma, and radioactive iodine-refractory differentiated thyroid cancer. "
Effect: modulate
Effect Info: "Vemurafenib and sorafenib treatment inhibited the phosphorylation of ERK1/2 and CSE1L in A375 melanoma cells and HT - 29 colorectal cancer cells, thereby suppressing tumors."
Note: drug comb
Score: 4.0
Pubmed(PMID): 26070816
Sentence Index:
Sentence:

Sequence & Structure:

MELSDANLQTLTEYLKKTLDPDPAIRRPAEKFLESVEGNQNYPLLLLTLLEKSQDNVIKVCASVTFKNYIKRNWRIVEDEPNKICEADRVAIKANIVHLMLSSPEQIQKQLSDAISIIGREDFPQKWPDLLTEMVNRFQSGDFHVINGVLRTAHSLFKRYRHEFKSNELWTEIKLVLDAFALPLTNLFKATIELCSTHANDASALRILFSSLILISKLFYSLNFQDLPEFFEDNMETWMNNFHTLLTLDNKLLQTDDEEEAGLLELLKSQICDNAALYAQKYDEEFQRYLPRFVTAIWNLLVTTGQEVKYDLLVSNAIQFLASVCERPHYKNLFEDQNTLTSICEKVIVPNMEFRAADEEAFEDNSEEYIRRDLEGSDIDTRRRAACDLVRGLCKFFEGPVTGIFSGYVNSMLQEYAKNPSVNWKHKDAAIYLVTSLASKAQTQKHGITQANELVNLTEFFVNHILPDLKSANVNEFPVLKADGIKYIMIFRNQVPKEHLLVSIPLLINHLQAESIVVHTYAAHALERLFTMRGPNNATLFTAAEIAPFVEILLTNLFKALTLPGSSENEYIMKAIMRSFSLLQEAIIPYIPTLITQLTQKLLAVSKNPSKPHFNHYMFEAICLSIRITCKANPAAVVNFEEALFLVFTEILQNDVQEFIPYVFQVMSLLLETHKNDIPSSYMALFPHLLQPVLWERTGNIPALVRLLQAFLERGSNTIASAAADKIPGLLGVFQKLIASKANDHQGFYLLNSIIEHMPPESVDQYRKQIFILLFQRLQNSKTTKFIKSFLVFINLYCIKYGALALQEIFDGIQPKMFGMVLEKIIIPEIQKVSGNVEKKICAVGITKLLTECPPMMDTEYTKLWTPLLQSLIGLFELPEDDTIPDEEHFIDIEDTPGYQTAFSQLAFAGKKEHDPVGQMVNNPKIHLAQSLHKLSTACPGRVPSMVSTSLNAEALQYLQGYLQAASVTLL

No data.

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

CSE1L-Ser112
Cancer Intensity
BRCA -0.406
COAD
HGSC
ccRCC -0.322
GBM -0.506
HNSC 1.705
LUAD 0.895
LUSC 0.636
non_ccRCC -0.578
PDAC
UCEC -1.424
CSE1L-Ser875
Cancer Intensity
BRCA 1.26
COAD
HGSC
ccRCC -0.557
GBM -1.005
HNSC
LUAD
LUSC
non_ccRCC
PDAC 0.302
UCEC
CSE1L-Ser931
Cancer Intensity
BRCA
COAD 1.09
HGSC
ccRCC
GBM
HNSC
LUAD -1.013
LUSC -1.05
non_ccRCC 0.81
PDAC
UCEC 0.163

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: